From Linda Stang, Alberta Health Services: As apixaban (Eliquis) is sure to start wreaking havoc in some of our special coag assays (read: tests will be ordered while patients are on this drug, but they WON’T tell us…), I did a search for publications about apixaban interference, and found nothing. Does anyone have any experience with interference in lupus anticoagulant panels (DRVVT– or SCT-based) or any other tests such as clot-based protein C or S assays, activated protein C resistance clot based assays, etc.?
Rivaroxaban (Xarelto) seems to be fairly obvious in our lupus anticoagulant panel as the DRVVT 1:1 mix samples are usually 75 seconds or above. They stand out like a sore thumb compared to the other patients, but I am not sure if any samples containing apixaban have come in, and just ‘slid under the radar.’
Thanks for your question, Linda. I’ll take a chance and suggest that apixaban will have the same effects on our clot-based assays as rivaroxaban, considering that both are direct anti-Xa anticoagulants, but I’ll ask for comments from those who have actually encountered apixaban in practice. Geo.